n this paper, we describe the first case of immune thrombocytopenic purpura (ITP) after an adenovirus-based SARS-CoV-2 vaccine. Some cases of ITP have already been described after the administration of both commercially available mRNA SARS-CoV-2 vaccines.1 A 28-years-old male presented to our Emergency Department (ED) on 8 March, 2021, because of oral bleeding and the appearance of petechiae over the trunk, arms, and legs for three days (Fig 1). He underwent a complete blood count showing 4 × 109/l platelets. Being a healthcare worker, he received the first dose of the AstraZeneca vaccine for Sars-CoV-2 on 14 February, 2021. Starting the next day, he experienced fatigue and headache for 10 days and fever for two days. His past medical history was completely negative, and his family history was negative for auto-immune and haematological diseases. The patient had undergone all the mandatory vaccinations without adverse effects. Physical examination showed purpura over the trunk, all four limbs, and bleeding lesions within the oral cavity. No hepatosplenomegaly and superficial lymphadenomegaly were observed.
Opmerkingen